Primary care health data warehouse authorised by the CNIL. 3,050 voluntary independent physicians, 3.1M+ active patients per year and 15 years of GP consultation history in France.
THIN® collects daily pseudonymised data from the medical software of voluntary general practitioners, providing a unique longitudinal view of the patient care pathway in the community.
Structured coding of pathologies, symptoms, medical history and consultation conclusions.
Complete history of drug prescriptions with dosage details, duration and renewals.
Laboratory tests, blood panels, HbA1c, creatinine, cholesterol and clinical risk scores.
Referrals to specialists, letters, results of outpatient consultations and hospital discharge summaries.
BMI, smoking, alcohol, allergies, family history and vaccination status.
THIN® meets the needs of epidemiology, pharmacovigilance, HEOR and Market Access teams.
Estimation of incidence and prevalence, identification of risk factors, characterisation of the burden of chronic diseases in the general population.
Analysis of diagnostic delays, treatment lines, switching and persistence. Comparison of practices among physicians in France.
Signal detection, post-authorisation pharmacovigilance studies (PASS), assessment of vaccine effectiveness in real-world conditions.
THIN® is one of the most cited databases in pharmacoepidemiology. Here is a selection of recent studies.
Retrospective descriptive study on THIN® France (2,000 GPs, 2010–2023). 4,402 axSpA patients. Mean diagnostic delay of 6.3 years.
Retrospective cohort study on THIN® France. 30,122 adults with Long COVID. Mean annual cost of €2,443 per patient.
3,249 incident patients in France (THIN®, 2015–2018). Only 40% receive treatment, highlighting major under-treatment and a high discontinuation rate.
263 COPD patients initiated on BUD/GLY/FOR triple therapy in THIN® France. 77% had experienced an exacerbation in the previous year. Adherence to SPLF guidelines: 69%.
Emulated cohort study on THIN® France (2,000 GPs, 2010–2019). 14,383 patients ≥75 years. Association between de-intensification and increased risk of death or hospitalisation at 3 months.
3,134 COPD patients initiated on triple therapy in THIN® France (2017–2019). Median persistence of 181 days for SITT vs 135 days for MITT (HR 1.47, p<0.001).
THIN® France holds a CNIL authorisation (deliberation N° 2025-15) and is referenced by the HAS, ANSM and CEPS. Data are provided by a network of voluntary physicians who are convinced that the longitudinal data observatory benefits research and medical progress, in compliance with GDPR.
From feasibility to publication, a structured process supported by our teams.
Free feasibility study on THIN® France data.
1–2 wks
Protocol writing and validation by the THIN® scientific committee.
4–6 wks
Cohort definition and extraction of variables according to the protocol.
2–3 wks
Descriptive analyses and modelling according to the statistical plan.
6–10 wks
Final report, support for congresses and journal submission.
4–6 wks
Contact our team to discuss the feasibility of your study on THIN® data in France.